Patent · US Active

Campaign-ready series of recombinant adeno-associated virus (rAAV) complementing plasmids

US11884926B2 · kind B2 · utility

0Cited by
1References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 1, 2019
Grant dateJan 30, 2024
Priority date
Expiry dateDec 23, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14171
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

In some aspects, the disclosure relates to compositions and methods for production of recombinant adeno-associated virus (rAAV) particles. The disclosure is based, in part, on isolated nucleic acids and systems that include only two vectors and are suitable for production of multiple different single gene viral vectors in a multiple small-scale campaign mode (e.g., 1013 to 1016 viral particles.)

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.